SAGE vs. HALO

In the year-to-date period, SAGE achieves a 31.68% return, which is significantly higher than HALO's 20.14% return. Over the past 10 years, SAGE has underperformed HALO with an annualized return of -16.44%, while HALO has yielded a comparatively higher 14.02% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Sage Therapeutics, Inc. (SAGE) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SAGE Sharpe Ratio is -0.93, which is lower than the HALO Sharpe Ratio of 1.47. The chart below compares the historical Sharpe Ratios of SAGE and HALO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SAGE nor HALO has paid dividends to shareholders.

The maximum SAGE drawdown since its inception was -97.51%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for SAGE and HALO. For additional features, visit the drawdowns tool.

Sage Therapeutics, Inc. (SAGE) has a higher volatility of 6.13% compared to Halozyme Therapeutics, Inc. (HALO) at 3.65%. This indicates that SAGE's price experiences larger fluctuations and is considered to be riskier than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Sage Therapeutics, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.